alvocidib Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Alvocidib is a flavonoid alkaloid CDK9 kinase inhibitor under clinical development by Tolero Pharmaceuticals for the treatment of acute myeloid leukemia. It has been studied also for the treatment of arthritis and atherosclerotic plaque formation. The target of alvocidib is the positive transcription elongation factor P-TEFb. Treatment of cells with alvocidib leads to inhibition of P-TEFb and the loss of mRNA production.   Wikipedia

Chemistry

  • SMILES: CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1
  • InChIKey: BIIVYFLTOXDAOV-YVEFUNNKSA-N
  • Mol. Mass: 401.85
  • ALogP: 3.3
  • ChEMBL Molecules:
    alvocidib  
    alvocidib hydrochloride  
More Chemistry

Pharmacology

Alternative names

alvocidib | alvocidib freebase | alvocidib hcl | alvocidib hydrochloride | (-)cis-5,7-dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4h-1-benzopyran-4-one | flavopiridol | flavopiridol hcl | hl-275 | hmr 1275 | hmr-1275 | l 868275 | l-868275 | l-86-8275 | l86-8275 | mdl-107826a | nsc-649890

Organizations (27)

Research & Development (27)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (64)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (64)


 

Anemia (Phase 1)

Anemia, Refractory (Phase 1)

Astrocytoma (Phase 1)

Breast Neoplasms (Phase 1/Phase 2)

Breast Neoplasms, Male (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Small Cell (Phase 1)

Endometrial Neoplasms (Phase 2)

Ependymoma (Phase 1)

Esophageal Neoplasms (Phase 2)

Gastrointestinal Stromal Tumors (Phase 1)

Glioma (Phase 1)

Hamartoma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Hodgkin Disease (Phase 1/Phase 2)

Intestinal Neoplasms (Phase 2)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 2)

Leukemia, Eosinophilic, Acute (Phase 2)

Leukemia, Hairy Cell (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia-Lymphoma, Adult T-Cell (Phase 1/Phase 2)

Leukemia, Monocytic, Acute (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myeloid, Chronic-Phase (Phase 1)

Leukemia, Myelomonocytic, Acute (Phase 2)

Leukemia, Prolymphocytic (Phase 2)

Liver Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 1/Phase 2)

Lymphoma, Follicular (Phase 1/Phase 2)

Lymphoma, Large-Cell, Anaplastic (Phase 1/Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 1/Phase 2)

Lymphoma, Mantle-Cell (Phase 1/Phase 2)

Lymphoma, Non-Hodgkin (Phase 1/Phase 2)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1)

Lymphoma, T-Cell (Phase 1/Phase 2)

Lymphomatoid Granulomatosis (Phase 1/Phase 2)

Medulloblastoma (Phase 1)

Melanoma (Phase 2)

Mesothelioma (Phase 1)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 1/Phase 2)

Neoplasms (Phase 1)

Neoplasms, Germ Cell and Embryonal (Phase 2)

Neuroblastoma (Phase 1)

Neuroectodermal Tumors (Phase 1)

Osteosarcoma (Phase 1)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)

Prostatic Neoplasms (Phase 2)

Retinoblastoma (Phase 1)

Rhabdomyosarcoma (Phase 1)

Sarcoma (Phase 2)

Sarcoma, Ewing (Phase 1)

Seminoma (Phase 2)

Sezary Syndrome (Phase 1/Phase 2)

Stomach Neoplasms (Phase 2)

Testicular Neoplasms (Phase 2)

Thrombocytopenia (Phase 1)

Thromboembolism (Phase 2)

Waldenstrom Macroglobulinemia (Phase 1/Phase 2)

Wilms Tumor (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 64
  • # of Trial Organizations: 27

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue